EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multi-institutional evaluation of Depo-Provera for the treatment of hot flashes associated with androgen ablation for prostate cancer



Multi-institutional evaluation of Depo-Provera for the treatment of hot flashes associated with androgen ablation for prostate cancer



Journal of Urology 171(4 Supplement): 384, April




(PDF 0-2 workdays service: $29.90)

Accession: 035349249

Download citation: RISBibTeXText



Related references

Depo-provera as a treatment for hot flashes in men on androgen ablation therapy. Journal of Urology 153(4 SUPPL ): 448A, 1995

Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. Journal of Urology 162(1): 98-102, 1999

Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. Journal of Urology 166(2): 517-520, August, 2001

Activity of aromathecins against African trypanosomes. Antimicrobial Agents and ChemoTherapy, 2018

Depo-provera therapy for hot flushes associated with hormonal treatment of advanced carcinoma of the prostate. Journal of Urology 159(5 SUPPL ): 132, 1998

Depo provera treatment for sex offending behavior: an evaluation of outcome. Bulletin of the American Academy of Psychiatry and the Law 20(3): 249-259, 1992

Apoptosis and other mechanisms in androgen ablation treatment and androgen independent progression of prostate cancer: a review. Cancer Detection and Prevention 22(5): 476-484, 1998

Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology 57(3): 518-523, March, 2001

Evaluation of the efficacy and safety of Salvia officinalis in controlling hot flashes in prostate cancer patients treated with androgen deprivation. PhytoTherapy Research 26(2): 208-213, 2012

Molecular analysis of the androgen receptor in prostate cancer specimens obtained before and after hormonal treatment Androgen ablation selects an androgen receptor with an expanded poly-glutamine repeat. Proceedings of the American Association for Cancer Research Annual Meeting (41): 238, March, 2000

Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study. International Journal of Radiation Oncology, Biology, Physics 86(3): 540-545, 2013

Reaction of estrogen and progesterone receptors in endometrial cancer to treatment with large doses of progestogen depo provera. Zentralblatt fuer Gynaekologie 112(17): 1111-1115, 1990

Response of estrogen and progesterone receptors to treatment with large doses of progestogen (depo-provera) in endometrial cancer. Zentralblatt für Gynakologie 112(17): 1111-1115, 1990

A multi-institutional evaluation of active surveillance for low risk prostate cancer. Journal of Urology 189(1 Suppl): S19-25; Discussion S25, 2013

Intermittent androgen ablation as a treatment for prostate cancer. Frontiers of Radiation Therapy and Oncology 36: 66-71, 2002